Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
2.
Infect Dis (Lond) ; 54(5): 367-377, 2022 05.
Article in English | MEDLINE | ID: mdl-34983302

ABSTRACT

BACKGROUND: Seasonal influenza causes substantial numbers of hospitalizations annually. We have characterized the clinical picture and treatment practice in hospitalized adult influenza patients and assessed whether clinical risk scores on admission or influenza type were associated with severe outcomes. METHODS: Clinical characteristics and risk scores on admission (CRB65, CRB, SIRS and quick Sequential Organ Failure Assessment [qSOFA]), treatment and severe outcomes (defined as: stay in intensive care unit (ICU), receiving oxygen supplementation or staying ≥5 days in hospital), were recorded in patients hospitalized with influenza at Oslo University Hospital, Norway, between 2014 and 2018. RESULTS: Among the 156 included patients, 52.6% had influenza A(H3N2), 32.6% influenza B and 12.8% influenza A(H1N1). Median age was 70 years and 59.6% of patients were ≥65 years. Nine (5.8%) of the patients were treated in ICU, 43.0% received oxygen and 47.4% stayed ≥5 days in hospital. Overall, 34.6% of the patients had a high CRB score on admission which was associated with stay in ICU and oxygen supplementation. Multivariate analyses identified age, and pneumonia (46.8%), but not influenza type, to be associated with severe outcomes. Antiviral treatment was given to 37.2% of the patients, while 77.6% received antibiotics. Only 25.5% of patients with influenza B received antiviral therapy. CONCLUSIONS: The influenza patients were mostly elderly, and few patients were treated in ICU. A high CRB score was associated with severe outcomes with possible implications for patient monitoring. Less than 40% of the patients received antiviral therapy, whereas the majority were treated with antibiotics, indicating potential for optimising treatment strategies.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Hospitalization , Humans , Influenza A Virus, H3N2 Subtype , Influenza, Human/drug therapy , Influenza, Human/epidemiology , Intensive Care Units
8.
J Infect ; 63(4): 308-16, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21781987

ABSTRACT

AIM: Explore the role of viral factors and immune response in patients with severe pandemic pdmH1N1 illness without significant co-morbidity. MATERIALS: Seven patients with pdmH1N1 influenza, bilateral chest X-rays infiltrates, requiring mechanical ventilator support were consecutively recruited. Seven age- and gender-matched healthy individuals served as controls. RESULTS: Four patients were viremic, two with the mutant D222G/N pdmH1N1.Microarray analyses of peripheral blood leukocytes suggested a marked granulocytes activation, but no up-regulation of inflammatory cytokine mRNA. Patients with severe pdmH1NI had a marked systemic complement activation, and in contrast to the lack of cytokine mRNA up-regulation in blood leukocytes, plasma levels of a broad range of inflammatory mediators, including IP-10, and mediators involved in pulmonary remodelling were markedly elevated. Patients with mutant virus had particularly high IP-10 levels, and the most pronounced complement activation. CONCLUSIONS: In severe pdmH1N1, viremia was common and the D222G/N mutant was found in half of the viremic patients. Host immune response was characterized by strong activation of the innate immune system, including complement and granulocytes activation, increased serum levels of inflammation and pulmonary remodelling markers, possibly contributing to the observed tissue damage. However, few patients were included and further studies are needed to characterize the immune response in severe pdmH1N1 infection.


Subject(s)
Immunity, Innate , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H1N1 Subtype/pathogenicity , Influenza, Human/pathology , Influenza, Human/virology , Mutation, Missense , Neuraminidase/genetics , Viral Proteins/genetics , Adult , Amino Acid Substitution , Complement System Proteins , Cytokines/blood , Cytokines/metabolism , Granulocytes/immunology , Humans , Influenza, Human/complications , Influenza, Human/immunology , Molecular Sequence Data , Prospective Studies , Radiography, Thoracic , Respiration, Artificial , Respiratory Insufficiency/epidemiology , Respiratory Insufficiency/pathology , Sequence Analysis, DNA , Viremia/epidemiology
9.
Cardiovasc Res ; 79(1): 195-203, 2008 Jul 01.
Article in English | MEDLINE | ID: mdl-18339644

ABSTRACT

AIMS: CXC ligand 16 (CXCL16) may be involved in inflammation and lipid metabolism, and we hypothesized a role for this chemokine in coronary artery disease (CAD). METHODS AND RESULTS: We performed clinical studies in CAD patients as well as experimental studies in cells with relevance to atherogenesis [i.e. endothelial cells, vascular smooth muscle cells (SMC), and peripheral blood mononuclear cells (PBMC)]. We also examined the ability of HMG-CoA reductase inhibitors (statins) to modulate CXCL16 levels both in vivo and in vitro. Our main findings were: (i) patients with stable (n = 40) and unstable (n = 40) angina had elevated plasma levels of CXCL16 compared with controls (n = 20); (ii) low-dose simvastatin (20 mg qd, n = 15) and high-dose atorvastatin (80 mg qd, n = 9) down-regulated plasma levels of CXCL16 during 6 months of therapy; (iii) in vitro, atorvastatin significantly decreased the interleukin (IL)-1beta-mediated release of CXCL16 from PBMC and endothelial cells; (iv) attenuating effect of atorvastatin on the IL-1beta-mediated release of CXCL16 in PBMC seems to involve post-transcriptional modulation as well as down-regulation of CXCL16 release through inhibition of the protease a disintegrin and metalloproteinase 10 (ADAM10); (v) soluble CXCL16 increased the release of IL-8, monocyte chemoattractant peptide 1, and matrix metalloproteinases in vascular SMC and increased the release of IL-8 and monocyte chemoattractant peptide 1 in PBMC, with particularly enhancing effects in cells from CAD patients. CONCLUSION: Our findings suggest that soluble CXCL16 could be linked to atherogenesis not only as a marker of inflammation, but also as a potential inflammatory mediator.


Subject(s)
Chemokines, CXC/metabolism , Coronary Artery Disease/metabolism , Down-Regulation/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Receptors, Scavenger/metabolism , Aged , Atorvastatin , Case-Control Studies , Cells, Cultured , Chemokine CCL2/metabolism , Chemokine CXCL16 , Chemokines, CXC/genetics , Coronary Artery Disease/drug therapy , Coronary Artery Disease/pathology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Heptanoic Acids/pharmacology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Interleukin-8/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Male , Middle Aged , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Pyrroles/pharmacology , Receptors, Scavenger/genetics , Simvastatin/pharmacology
10.
Arterioscler Thromb Vasc Biol ; 28(5): 1005-11, 2008 May.
Article in English | MEDLINE | ID: mdl-18276907

ABSTRACT

OBJECTIVE: We examined the role of the CXCR2 ligand growth-related oncogene (GRO) alpha in human atherosclerosis. METHODS AND RESULTS: GROalpha levels were examined by enzyme immunoassay, real-time quantitative RT-PCR, and cDNA microarrays. The in vitro effect of statins on GROalpha was examined in endothelial cells and THP-1 macrophages. Our main findings were: (1) GROalpha was among the 10 most differentially expressed transcripts comparing peripheral blood mononuclear cells (PBMCs) from patients with coronary artery disease (CAD) and healthy controls. (2) Both patients with stable (n=41) and particularly those with unstable (n=47) angina had increased plasma levels of GROalpha comparing controls (n=20). (3) We found increased expression of GROalpha within symptomatic carotid plaques, located to macrophages and endothelial cells. (4) GROalpha enhanced the release of matrix metalloproteinases in vascular smooth muscle cells, and increased the binding of acetylated LDL in macrophages. (5) Atorvastatin downregulated GROalpha levels as shown both in vitro in endothelial cells and macrophages and in vivo in PBMCs from CAD patients. (6) The effect on GROalpha in endothelial cells involved increased storage and reduced secretion of GROalpha. CONCLUSIONS: GROalpha could be involved in atherogenesis and plaque destabilization, potentially contributing to inflammation, matrix degradation, and lipid accumulation within the atherosclerotic lesion.


Subject(s)
Carotid Stenosis/metabolism , Chemokine CXCL1/metabolism , Coronary Artery Disease/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Angina, Unstable/metabolism , Angina, Unstable/pathology , Aorta/metabolism , Aorta/pathology , Carotid Stenosis/pathology , Case-Control Studies , Cells, Cultured , Chemokine CXCL1/genetics , Coronary Artery Disease/pathology , Down-Regulation , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Enzyme Inhibitors/pharmacology , Female , Humans , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Macrophages/metabolism , Macrophages/pathology , Male , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 3/metabolism , Middle Aged , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Umbilical Veins/metabolism , Umbilical Veins/pathology
11.
Arterioscler Thromb Vasc Biol ; 27(3): 614-20, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17170367

ABSTRACT

OBJECTIVE: Based on their role in T-cell homing into nonlymphoid tissue, we examined the role of the homeostatic chemokines CCL19 and CCL21 and their common receptor CCR7 in coronary artery disease (CAD). METHODS AND RESULTS: We performed studies in patients with stable (n=40) and unstable (n=40) angina and healthy controls (n=20), in vitro studies in T-cells and macrophages, and studies in apolipoprotein-E-deficient (ApoE-/-) mice and human atherosclerotic carotid plaques. We found increased levels of CCL19 and CCL21 within the atherosclerotic lesions of the ApoE-/- mice, in human atherosclerotic carotid plaques, and in plasma of CAD patients. Whereas strong CCR7 expression was seen in T-cells from murine and human atherosclerotic plaques, circulating T-cells from angina patients showed decreased CCR7 expression. CCL19 and CCL21 promoted an inflammatory phenotype in T-cells and macrophages and increased matrix metalloproteinase (MMP) and tissue factor levels in the latter cell type. Although aggressive statin therapy increased CCR7 and decreased CCL19/CCL21 levels in peripheral blood from CAD patients, conventional therapy did not. CONCLUSIONS: The abnormal regulation of CCL19 and CCL21 and their common receptor in atherosclerosis could contribute to disease progression by recruiting T-cells and macrophages to the atherosclerotic lesions and by promoting inflammatory responses in these cells.


Subject(s)
Chemokines, CC/metabolism , Coronary Disease/blood , Coronary Disease/drug therapy , Heptanoic Acids/therapeutic use , Pyrroles/therapeutic use , Simvastatin/therapeutic use , Angioplasty, Balloon, Coronary/methods , Animals , Apolipoproteins E/deficiency , Atherosclerosis/metabolism , Atherosclerosis/pathology , Atherosclerosis/prevention & control , Atorvastatin , Biopsy, Needle , Cells, Cultured , Chemokine CCL19 , Chemokine CCL21 , Chemokines, CC/genetics , Coronary Disease/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Gene Expression Regulation , Humans , Immunohistochemistry , In Vitro Techniques , Leukocytes, Mononuclear , Mice , Mice, Transgenic , Prognosis , RNA, Messenger/analysis , Receptors, CCR7 , Receptors, Chemokine/metabolism , Reference Values , Risk Factors , Sensitivity and Specificity , Treatment Outcome
12.
J Am Coll Cardiol ; 48(8): 1591-9, 2006 Oct 17.
Article in English | MEDLINE | ID: mdl-17045893

ABSTRACT

OBJECTIVES: We sought to investigate the role of the CXC chemokine neutrophil-activating peptide-2 (NAP-2) in atherogenesis and plaque destabilization. BACKGROUND: Chemokines are involved in atherogenesis, but the role of NAP-2 in atherosclerotic disorders is unclear. Based on its potential pro-atherogenic properties, we hypothesized a pathogenic role for NAP-2 in coronary artery disease. METHODS: We tested this hypothesis by differential experimental approaches including studies in patients with stable (n = 40) and unstable angina (n = 40) and healthy control subjects (n = 20). RESULTS: The following results were discovered: 1) patients with stable, and particularly those with unstable, angina had markedly raised plasma levels of NAP-2 compared with control subjects, accompanied by increased expression of CXC receptor 2 in monocytes; 2) platelets, but also peripheral blood mononuclear cells (PBMCs), released large amounts of NAP-2 upon stimulation, with a particularly prominent PBMC response in unstable angina; 3) NAP-2 protein was detected in macrophages and smooth muscle cells of atherosclerotic plaques and in monocytes and platelets of coronary thrombi; 4) in vitro, recombinant and platelet-derived NAP-2 increased the expression of adhesion molecules and chemokines in endothelial cells; and 5) whereas aspirin reduced plasma levels of NAP-2, statin therapy increased NAP-2 with stimulating effects both on platelets and leukocytes. CONCLUSIONS: Our findings suggest that NAP-2 has the potential to induce inflammatory responses within the atherosclerotic plaque. By its ability to promote leukocyte and endothelial cell activation, such a NAP-2-driven inflammation could promote plaque rupture and acute coronary syndromes.


Subject(s)
Coronary Disease/blood , beta-Thromboglobulin/metabolism , Acute Disease , Angina Pectoris/blood , Angina, Unstable/blood , Arteries , Aspirin/pharmacology , Blood Platelets/metabolism , Cell Adhesion Molecules/metabolism , Cells, Cultured , Chemokines/metabolism , Chemotaxis/drug effects , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Intracranial Arteriosclerosis/metabolism , Intracranial Arteriosclerosis/pathology , Macrophages/metabolism , Monocytes/drug effects , Monocytes/metabolism , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/metabolism , Platelet Count , Receptors, Peptide/blood , Receptors, Peptide/metabolism , Recombinant Proteins/pharmacology , Syndrome , T-Lymphocytes/metabolism , Thrombosis/blood , Vasculitis/etiology , beta-Thromboglobulin/pharmacology
13.
Arterioscler Thromb Vasc Biol ; 26(1): 200-5, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16254204

ABSTRACT

OBJECTIVE: Increasing data support the involvement of chemokines in atherogenesis. However, although several studies have shown increased chemokine levels in adult patients, the literature is virtually devoid of data on chemokines in children with hypercholesterolemia. METHODS AND RESULTS: We examined the gene expression of chemokines in peripheral blood mononuclear cells (PBMCs) from clinically healthy children with and without heterozygous familial hypercholesterolemia (FH). Our main findings were: (1) compared with healthy controls, PBMCs from FH children showed significantly higher mRNA levels of RANTES, but not of the other examined chemokines; (2) an opposite pattern was seen in adult FH subjects, with markedly enhanced expression of macrophage inflammatory peptide-1alpha, but not of RANTES; (3) this increased gene expression of RANTES in PBMCs from FH children seemed to reflect enhanced RANTES expression in monocytes but not in T cells; (4) FH children also had raised serum levels of neopterin, additionally suggesting monocyte/macrophage activation in these children; and (5) PBMCs from both FH children and controls showed enhanced release of interleukin 8 on RANTES stimulation in vitro. CONCLUSIONS: Our findings support a role of inflammation also in the early stages of atherogenesis possibly involving monocyte-derived RANTES as an important mediator.


Subject(s)
Chemokine CCL5/genetics , Chemokine CCL5/metabolism , Hyperlipoproteinemia Type II/genetics , Hyperlipoproteinemia Type II/immunology , Adolescent , Adult , Atherosclerosis/genetics , Atherosclerosis/immunology , Atherosclerosis/metabolism , Cells, Cultured , Chaperonin 60/pharmacology , Chemokine CCL4 , Child , Female , Heterozygote , Humans , Hyperlipoproteinemia Type II/metabolism , Interleukin-8/genetics , Interleukin-8/metabolism , Lipoproteins, LDL/pharmacology , Macrophage Inflammatory Proteins/genetics , Macrophage Inflammatory Proteins/metabolism , Male , Middle Aged , Monocytes/cytology , Monocytes/drug effects , Monocytes/metabolism , Neopterin/blood , RNA, Messenger/analysis , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Up-Regulation/immunology
14.
Future Cardiol ; 2(1): 75-83, 2006 Jan.
Article in English | MEDLINE | ID: mdl-19804134

ABSTRACT

Considerable progress has been made in the understanding of atherogenesis and atherosclerosis is now considered to be an inflammatory disease of the vessel wall involving several cell types, such as endothelial cells, smooth muscle cells and macrophages. Progression of an atheroslerotic lesion can lead to vulnerable and rupture-prone plaques, causing thrombus formation and the development of acute coronary syndromes. The balance between inflammatory (e.g., tumor necrosis factor-alpha, interleukin-6,) and anti-inflammatory cytokines (e.g., IL-10) seems to be of critical importance in the pathogenesis of plaque formation and destabilization, and it has recently been suggested that an inflammatory imbalance in unstable disease with inadequately raised IL-10 levels is also of importance. This lack of IL-10-mediated responses could promote inflammation, enhance oxidative stress and foam cell apoptosis, leading to plaque destabilization and thrombus formation and the development of acute coronary syndromes. Based on these issues, IL-10 has been postulated as an immunological scalpel in atherosclerotic disorders. Knowledge of IL-10 as a modulator of plaque stability may provide multiple opportunities for the treatment and prevention of atherosclerotic diseases in the future.

15.
Expert Rev Cardiovasc Ther ; 3(6): 1111-24, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16293001

ABSTRACT

Understanding of the mechanisms underlying atherosclerotic disorders has evolved beyond the view of a progressive collection of lipids and cellular debris in the vascular wall. Current evidence has implicated inflammatory pathways as an important pathogenic mechanism in atherogenesis and plaque destabilization. Although not necessarily the primary event, inflammation and cytokine activation during plaque formation and destabilization may represent a common final pathway to various stimuli. Thus, it seems that not only 'new' risk factors, such as infections with various microorganisms, but also classic risk factors for cardiovascular disease, such as hyperlipidemia, hypertension and diabetes, may promote their atherogenic effects through inflammatory responses. Indeed, recent reports have suggested that traditional cardiovascular medications may attenuate atherogenesis and enhance plaque stability, at least partly through anti-inflammatory mechanisms. However, uncovering the inflammatory pathways in atherosclerosis has raised the possibility that newer treatment modalities should be more directly targeted against inflammatory mediators. Recently, a series of experimental studies have reported reduction of atherosclerosis by immunomodulatory therapy, such as chemokine blockade, interleukin-10 and immunization/vaccination against oxidized low-density lipoprotein and heat-shock protein. It is conceivable that some of these approaches will be tested clinically and, if successful, they could provide novel treatment strategies in coronary artery disease in humans.


Subject(s)
Coronary Artery Disease/drug therapy , Coronary Artery Disease/etiology , Immunologic Factors/therapeutic use , Inflammation/complications , Animals , Humans
16.
Arterioscler Thromb Vasc Biol ; 25(12): 2567-72, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16224053

ABSTRACT

OBJECTIVE: Recent data derived primarily from studies in animal models suggest that fractalkine (CX3CL1) and its cognate receptor, CX3CR1, play a role in atherogenesis. We, therefore, hypothesized that enhanced CX3CL1/CX3CR1 expression may promote atherogenesis in patients with coronary artery disease (CAD). METHODS AND RESULTS: We examined the plasma levels of CX3CL1 and CX3CR1 expression in peripheral blood mononuclear cells (PBMC) in various CAD populations (30 patients with previous myocardial infarction, 40 patients with stable angina, 40 patients with unstable angina, and a total of 35 controls) and used various experimental approaches to characterize CX3CL1-mediated leukocyte responses. We found that the plasma levels of CX3CL1 are greatly increased in CAD, particularly in unstable disease. The parallel increase of CX3CR1 expression in PBMC was predominantly attributable to an expansion of the (CX3CR1+)(CD3+)(CD8+) T cell subset and was associated with enhanced chemotactic, adhesive, and inflammatory responses to CX3CL1. Statin therapy for 6 months reduced the expression of CX3CL1 and CX3CR1, reaching statistical significance for both parameters only during aggressive (atorvastatin, 80 mg qd) but not conventional (simvastatin, 20 mg qd) therapy. Consequently, the functional responses of the PBMC to CX3CL1 including migration, adhesion, and secretion of interleukin-8 were attenuated by the treatments. CONCLUSIONS: Our results suggest that the CX3CL1/CX3CR1 dyad may contribute to atherogenesis and plaque destabilization in human CAD.


Subject(s)
Chemokines, CX3C/blood , Coronary Artery Disease/drug therapy , Coronary Artery Disease/physiopathology , Heptanoic Acids/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Membrane Proteins/blood , Membrane Proteins/genetics , Pyrroles/administration & dosage , Receptors, Chemokine/genetics , Angina, Unstable/drug therapy , Angina, Unstable/metabolism , Angina, Unstable/physiopathology , Atorvastatin , CX3C Chemokine Receptor 1 , Cell Adhesion/drug effects , Cells, Cultured , Chemokine CX3CL1 , Chemokines, CX3C/genetics , Chemokines, CX3C/pharmacology , Chemotaxis/drug effects , Cholesterol, LDL/blood , Coronary Artery Disease/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Gene Expression/drug effects , Gene Expression/physiology , Humans , Interleukin-8/metabolism , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Membrane Proteins/pharmacology , Myocardial Infarction/drug therapy , Myocardial Infarction/metabolism , Myocardial Infarction/physiopathology , Simvastatin/administration & dosage , Umbilical Veins/cytology
17.
Expert Opin Pharmacother ; 6(13): 2169-80, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16218879

ABSTRACT

Our understanding of the mechanisms underlying acute coronary syndromes has evolved beyond the view that this syndrome reflects a progressive collection of lipids and cellular debris in the vascular wall. Current evidence has implicated a role for inflammation in the pathogenesis of this process. Thus, inflammatory cytokines may attenuate interstitial collagen synthesis, increase matrix degradation and promote apoptosis in several atheroma-associated cell types, and all these cellular events may enhance plaque vulnerability. Recently, a series of experimental studies have reported the plaque-stabilising effects of immunomodulatory therapy such as chemokine blockade, anti-CD40 ligand and IL-10. It is conceivable that some of these approaches will be tested clinically and, if successful, they could provide novel treatment strategies for atherosclerotic plaque stabilisation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Coronary Artery Disease/drug therapy , Endothelium, Vascular/drug effects , Immunologic Factors/pharmacology , Interleukin-10/pharmacology , Muscle, Smooth, Vascular/drug effects , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , CD40 Ligand/antagonists & inhibitors , CD40 Ligand/immunology , Chemokines/antagonists & inhibitors , Chemokines/immunology , Coronary Artery Disease/immunology , Coronary Artery Disease/prevention & control , Drug Evaluation, Preclinical , Endothelium, Vascular/immunology , Endothelium, Vascular/pathology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunologic Factors/therapeutic use , Inflammation/drug therapy , Inflammation/immunology , Interleukin-10/therapeutic use , Muscle, Smooth, Vascular/immunology
18.
J Lipid Res ; 46(2): 211-9, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15547296

ABSTRACT

Interleukin (IL)-10 may have a therapeutic potential in atherosclerosis, but its mechanisms of action have not been clarified. Foam cell formation is a key event in atherogenesis, and apoptosis of these lipid-laden cells may promote plaque destabilization. We sought to explore whether IL-10 could have plaque-stabilizing properties in acute coronary syndromes (ACS). We studied the effect of IL-10 on oxidized low density lipoprotein (oxLDL)-stimulated THP-1 cells and monocyte-derived macrophages from ACS patients and healthy controls using different experimental approaches. Our main findings were: i) IL-10 enhances lipid accumulation in oxLDL-stimulated THP-1 macrophages, at least partly by counteracting oxLDL-induced apoptosis; ii) This antiapoptotic effect of IL-10 involves increased expression of the antiapoptotic genes Bfl-1 and Mcl-1, accompanied by protective effects on mitochondria function; iii) By silencing Bfl-1 and Mcl-1 genes using siRNAs, we were able to abolish this IL-10-mediated effect on lipid accumulation; iv) IL-10 also induced lipid accumulation in oxLDL-stimulated macrophages from patients with ACS, but not in macrophages from healthy controls; v) In ACS patients, this enhancing effect of IL-10 on lipid accumulation was accompanied by enhanced Mcl-1 expression. No such antiapoptotic effect was seen in macrophages from healthy controls. These findings suggest a new mechanism for the effect of IL-10 in atherosclerosis, possibly contributing to plaque stabilization.


Subject(s)
Apoptosis , Foam Cells/metabolism , Interleukin-10/physiology , Lipoproteins, LDL/metabolism , Macrophages/metabolism , Arteriosclerosis , Azo Compounds/pharmacology , Case-Control Studies , Cells, Cultured , Dose-Response Relationship, Drug , Humans , Interleukin-10/metabolism , Leukocytes, Mononuclear/metabolism , Lipid Metabolism , Minor Histocompatibility Antigens , Mitochondria/metabolism , Monocytes/metabolism , Myeloid Cell Leukemia Sequence 1 Protein , Neoplasm Proteins/biosynthesis , Oxygen/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , RNA, Messenger/metabolism , RNA, Small Interfering/metabolism , Time Factors , Transfection
19.
Thromb Haemost ; 92(6): 1358-67, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15583745

ABSTRACT

Platelets may act as inflammatory cells. To study the effects of soluble and cell-bound platelet factors on the expression of several cytokines and related mediators in leukocytes, peripheral blood mononuclear cells (PBMC) were incubated with platelet-free supernatants from SFLLRN-activated platelet-rich plasma (PRP) or SFLLRN-activated PRP in itself. Our main findings were: (i) the gene expression of several chemokines and some cytokines were markedly increased by both activated PRP and supernatants, as also confirmed at the protein level for IL-6, IL-8 and MIP-1alpha; (ii) the selective protein kinase A type I (PKAI) antagonist Rp-8-Br-cAMP reduced this platelet-induced expression of IL-6, IL-8 and MIP-1alpha in PBMC, suggesting a role of cAMP/PKAI mediated mechanisms in this interaction; (iii) PGE(2) dose-dependently increased the release of IL-6, IL-8 and MIP-1alpha from PBMC mimicking the effect of activated platelets. Furthermore, activated platelets released comparable amounts of PGE(2), suggesting that platelet-derived PGE2 could interact with PBMC in co-cultures; (iv) IL-10 inhibited the platelet-inducing effect on IL-6, IL-8 and MIP-1alpha in PBMC, and notably, the addition PGE2 totally abolished this IL-10 effect suggesting that the suppressive effect of IL-10 on the plateletinduced activation of PBMC might at least partly involve PGE(2) related mechanisms. The present study supports a view of platelets as inflammatory cells, and suggests a potential role of platelet-derived PGE(2) in platelet-induced inflammatory responses.


Subject(s)
Cytokines/biosynthesis , Dinoprostone/physiology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Platelet Activation , Adult , Cells, Cultured , Chemokine CCL3 , Chemokine CCL4 , DNA, Complementary/metabolism , Dinoprostone/metabolism , Dose-Response Relationship, Drug , Female , Gene Expression Regulation, Enzymologic , Humans , Immunoenzyme Techniques , Inflammation , Interleukin-10/metabolism , Interleukin-10/physiology , Interleukin-6/metabolism , Interleukin-8/metabolism , Leukocytes, Mononuclear/immunology , Macrophage Inflammatory Proteins/metabolism , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction
20.
J Am Coll Cardiol ; 44(2): 369-75, 2004 Jul 21.
Article in English | MEDLINE | ID: mdl-15261933

ABSTRACT

OBJECTIVES: We sought to investigate whether activin A could be involved in the immunopathogenesis of acute coronary syndromes. BACKGROUND: Inflammatory mechanisms seem to play a pathogenic role in atherosclerosis and acute coronary syndromes, but the actual mediators have not been fully identified. Activin A, a pleiotropic member of the transforming growth factor-beta cytokine family, has recently been suggested to play a role in inflammation. METHODS: We examined the role of activin A and its endogenous inhibitor follistatin in patients with stable (n = 26) and unstable angina (n = 20) and healthy control subjects (n = 20) by different experimental approaches. RESULTS: 1) Patients with stable angina had raised activin A concentrations, as assessed by protein levels in serum and messenger ribonucleic acid levels in peripheral blood mononuclear cells (PBMCs). 2) Although several activin A-related mediators were upregulated in PBMCs from patients with stable angina compared with controls (i.e., activin A and Smad3), no changes or even downregulation (i.e., Smad2) were seen in unstable disease. 3) The activin type II receptors, representing the primary ligand-binding proteins, were downregulated in unstable compared with stable angina. 4) Percutaneous coronary intervention induced a decrease in the activin A/follistatin ratio, suggesting downregulatory effects on activin A activity. 5) Although activin A dose-dependently suppressed the release of inflammatory cytokines from PBMCs in angina patients, an opposite effect was found in healthy controls. CONCLUSIONS: Our findings suggest an anti-inflammatory potential of activin A in angina patients, and such effects may be of particular relevance in unstable angina in which several of the activin parameters were downregulated.


Subject(s)
Activins/blood , Angina, Unstable/blood , Inhibin-beta Subunits/blood , Activins/genetics , Activins/physiology , Angina, Unstable/physiopathology , Angina, Unstable/therapy , Angioplasty, Balloon, Coronary , Cells, Cultured , Cytokines/metabolism , DNA-Binding Proteins/blood , Female , Follistatin/blood , Follistatin/genetics , Gene Expression , Humans , Inflammation , Inflammation Mediators/blood , Inhibin-beta Subunits/genetics , Inhibin-beta Subunits/physiology , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , RNA, Messenger/blood , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Smad Proteins , Trans-Activators/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...